29 reports

  • 6.1 INTRODUCTION
  • FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016-2023 (USD MILLION)

PREBIOTICS RESIST GASTRIC ACIDITY AND HYDROLYSIS CAUSED BY ENZYMES AND GASTROINTESTINAL ABSORPTION.

  • Mineral Supplement
  • United States
  • Market Size
  • Arla Foods
  • Cargill Inc.

One of the major reasons for the high bioavailability of organic minerals is that, unlike inorganic minerals, these do not interact with fiber, tannin, phytate, silicates, oxalate, or other minerals in the gastrointestinal tract.

  • Mineral Supplement
  • Pig
  • World
  • Alltech Inc.
  • Kemin Industries, Inc.

THE MICROPEARLS SPRAY FREEZING TECHNOLOGY ALLOWS FOR THE TIMELY RELEASE OF THESE ## KEY NUTRIENTS THROUGHOUT AN ANIMAL' S GASTROINTESTINAL TRACT.

  • Mineral Supplement
  • North America
  • United States
  • World
  • Market Size
  • VITAMIN & MINERAL PREMIXES MARKET, BY FUNCTIONALITY

Q. ##.

  • Mineral Supplement
  • World
  • Market Size
  • Glanbia plc
  • Nutreco N.V.

MARKET ##.

  • Mineral Supplement
  • APAC
  • Japan
  • World
  • Demand

You can easily book an appointment with one online.

  • Mineral Supplement
  • World
  • Market Size
  • Alltech Inc.
  • Kemin Industries, Inc.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Mineral Supplement
  • China
  • Demand
  • Amway Corporation
  • Joincare Pharmaceutical Group Industry Co., Ltd.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Energy
  • Mineral Supplement
  • Vitamin
  • China
  • Demand
  • ATRIPLA SWOT ANALYSIS, 2016

BIOSCIENCE TRENDS; ##(##): ##-##.

  • Hepatitis Treatment
  • Mineral Supplement
  • East Asia
  • Gilead Sciences, Inc.
  • ViiV Healthcare Ltd.

Genotype ## is the most common HCV.

  • Hepatitis Treatment
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

It is estimated that worldwide one in five men and one in three women are at risk of an osteoporotic fracture.

  • Mineral Supplement
  • World
  • Forecast
  • Quidel Corporation
  • Roche Group

The subsidiary is focused on aging care, critical care & surgery, gastrointestinal function, and pediatrics.

  • Mineral Supplement
  • North America
  • United States
  • Demand
  • Market Size

Q. ##.

  • Mineral Supplement
  • United States
  • Cargill Inc.
  • Koninklijke DSM N.V.
  • Nutreco N.V.

Elvitegravir inhibits HIV-## integrase.

  • Hepatitis Treatment
  • United States
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Clinical Trial profile. 187 Trial Title
  • Clinical Trial profile. 341 Trial Title

The prominent features of this report are - ##.

  • Cytokine
  • Hepatitis Treatment
  • Mineral Supplement
  • Pharmaceutical
  • World
  • Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir

The drug candidate acts by inhibiting Gag protein (HIV-## Maturation Inhibitor).

  • Hepatitis Treatment
  • Mineral Supplement
  • Pharmaceutical
  • India
  • Hetero Drugs Limited

This agreement enables Beactica to advance one of their prioritized discovery programmes and enables Medivir to search for hits active against one of its early discovery targets.

  • Healthcare
  • Hepatitis Treatment
  • Pharmaceutical
  • Sweden
  • Medivir UK Ltd.

Deal Rationale Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases.

  • Hepatitis Treatment
  • Pharmaceutical
  • United States
  • Company
  • ContraVir Pharmaceuticals, Inc.

One unit refers to one test kit.

  • Hepatitis
  • Hepatitis Treatment
  • Mineral Supplement
  • RNA
  • Abbott

The prominent features of this report are - ##.

  • Cardiology
  • Mineral Supplement
  • Therapy
  • World
  • Product Initiative

We grew faster than the market in ## out of our ## top therapies - Respiratory, Anti-infectives, Gastrointestinal and Urology.

  • Hepatitis Treatment
  • Pharmaceutical
  • India
  • Company
  • Cipla Ltd
  • ANTISENSE RNAI OLIGONUCLEOTIDE TO INHIBIT MIR-122 FOR HEPATITIS C - DRUG PROFILE
  • ANTISENSE RNAI OLIGONUCLEOTIDE TO INHIBIT MIR-122 FOR HEPATITIS C - DRUG PROFILE

RESULTS FROM THE PHASE I/ II STUDY WERE PRESENTED AT THE 2017 GASTROINTESTINAL CANCERS SYMPOSIUM.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Hepatitis
  • Hepatitis Treatment
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Bristol-Myers Squibb Company ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Bukwang Pharm Co Ltd ## ## ## ## ## ##

  • Hepatitis
  • Hepatitis Treatment
  • Mineral Supplement
  • World
  • GlaxoSmithKline plc
  • HIV-1 INFECTION - PIPELINE BY JOHNSON & JOHNSON, H2 2015

The only dose-limiting toxicities (DLTs) were gastrointestinal in nature.

  • Hepatitis Treatment
  • Mineral Supplement
  • Vaccine
  • United States
  • Gilead Sciences, Inc.

DIGESTION: THE ENZYMATIC HYDROLYSIS OF MAJOR NUTRIENTS IN THE GASTROINTESTINAL SYSTEM TO YIELD THEIR BUILDING-BLOCK COMPONENTS.

  • Antiviral
  • Hepatitis Treatment
  • Mineral Supplement
  • United States
  • Gilead Sciences, Inc.
  • CAPSID PROTEIN INHIBITOR CAPSID PROTEIN
  • 3 1 NS3/4A PROTEASE INHIBITOR HEPACIVIRIN (NS3/4A PROTEASE OR NS3 SERINE PROTEINASE OR EC 3.4.21.98)

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Hepatitis Treatment
  • Mineral Supplement
  • Pharmaceutical
  • World

In general, it is assumed that prebiotics mainly increase the activity of lactobacilli and bifidobacteria in the gastrointestinal tract.

  • Mineral Supplement
  • Europe
  • European Union
  • World
  • Market Size

Inhibitor ## ## ## ## ## ## ## Cytochrome P## ##A## (CYP##A##) Inhibitor ## ## ## ## ## ## ## Endothelin Receptor A (ETA) Antagonist ## ## ## ## ## ## ## Histone Deacetylases (HDAC) Inhibitor ## ## ## ## ## ## ## HIV Integrase Inhibitor ## ## ## ## ## ##

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Company Operations
  • Gilead Sciences, Inc.